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Tuberous sclerosis is caused by mutations in the TSC1 or TSC2 gene and characterized by development of tumors
in multiple organs including the kidneys. TSC-associated tumors exhibit somatic loss of the second allele of the
TSC genes, leading to aberrant activation of the mechanistic target of rapamycin (mTOR) signaling pathway.
Activation of mTOR complex 1 (mTORC1) causes addiction to glucose and glutamine in Tsc1−/− or Tsc2−/− mouse
embryonic fibroblasts (MEFs). Blocking of glutamine anaplerosis in combination with glycolytic inhibition causes
significant cell death in Tsc2−/− but not Tsc2+/+ MEFs. In this study, we tested efficacy of dual inhibition of
glycolysis with 3-BrPA and glutaminolysis with CB-839 for renal tumors in Tsc2+/− mice. Following 2 months of
treatment of Tsc2+/− mice from the age of 12 months, combination of 3-BrPA and CB-839 significantly reduced
overall size and cellular areas of all renal lesions (cystic/papillary adenomas and solid carcinomas), but neither
alone did. Combination of 3-BrPA and CB-839 inhibited mTORC1 and the proliferation of tumor cells but did not
increase apoptosis. However, combination of 3-BrPA and CB-839 was not as efficacious as rapamycin alone or
rapamycin in combination with either 3-BrPA or CB-839 for renal lesions of Tsc2+/− mice. Consistently, rapamycin
alone or rapamycin in combination with either 3-BrPA or CB-839 had stronger inhibitory effects on mTORC1 and
proliferation of tumor cells than combination of 3-BrPA and CB-839. We conclude that combination of 3-BRPA and
CB-839 may not offer a better therapeutic strategy than rapamycin for TSC-associated tumors.
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Tuberous sclerosis is caused by mutations in the TSC1 or TSC2 gene
and characterized by development of tumors in different organs [1].
Over 80% of TSC patients develop multiple and bilateral angiomyo-
lipomas in the kidneys that are the leading cause of adult deaths from the
disease. Around 50% of TSC patients have renal cysts, and
approximately 4% of TSC patients suffer from renal carcinomas. The
TSC1/TSC2 complex downregulates the mechanistic target of
rapamycin (mTOR) signaling pathway through its GTPase activating
protein (GAP) activity towards the small G-protein Rheb (Ras
homologue enriched in brain) [2]. TSC-associated tumors exhibit
somatic loss of the second allele of the TSC genes, giving rise to aberrant
activation of the mTOR signaling pathway in human and mouse [3,4].
Rapamycin and its analogs (rapalogs) are allosteric mTOR inhibitors
and reduce size of TSC-associated tumors, but these tumors regrow
upon cessation of treatment [5–7]. Activation of mTOR complex 1
(mTORC1) promotes glycolysis and glutaminolysis in Tsc2−/− mouse
embryonic fibroblasts (MEFs) that are addicted to glucose andglutamine [8,9]. Glycolytic inhibition suppresses tumor growth in a
mouse model transplanted with Tsc2−/− rat tumor cells [10]. Blocking
of glutamine anaplerosis in combination with glycolytic inhibition
causes significant cell death in Tsc2−/− but not Tsc2+/+ MEF cells [9].
Dual inhibition of glycolysis and glutaminolysis may provide a new
approach to treating tumors lacking TSC1 or TSC2.
The pyruvate analog 3-bromopyruvate (3-BrPA) is an efficient
inhibitor of glycolysis through alkylating glycolytic enzymes,
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dehydrogenase (GAPDH) [11]. Being well tolerated, 3-BrPA is very
effective for treating liver carcinomas in rabbit and mouse models [12].
CB-839 is a potent blocker of glutaminolysis by selectively inhibiting
glutaminase (GLS). Preclinical studies have suggested effective
antitumor activity of CB-839 in various types of cancer [13–16].
In this study, we tested efficacy of dual inhibition of glycolysis with
3-BrPA and glutaminolysis with CB-839 for renal tumors in Tsc2+/−
mice. We found that combination of 3-BrPA and CB-839
significantly reduced overall size and cellular areas of all renal lesions
including cystic/papillary adenomas and solid carcinomas, but neither
alone did. However, combination of 3-BrPA and CB-839 was not as
efficacious as rapamycin alone or rapamycin in combination with
either 3-BrPA or CB-839 for renal tumors of Tsc2+/− mice.
Materials and Methods
Animal Procedures
Animal procedures were performed in accordance with the UK
Home Office guidelines and approved by the Ethical Review Group of
Cardiff University.Tsc2+/−mice were described previously [17]. To test
antitumor efficacy of dual inhibition of glycolysis and glutaminolysis for
renal tumors, Tsc2+/− balb/c litter mates were randomly allocated into
seven groups, balanced for gender and of the same age. Tsc2+/− mice
were treated for 2 months from the age of 12 months with vehicle
(10 μl/g) (n = 17), 3-BrPA (3 mg/kg) (n = 19), CB-839 (200 mg/kg)
(n = 20), rapamycin (4 mg/kg) (n = 20), 3-BrPA (3 mg/kg) plus
rapamycin (4 mg/kg) (n = 18), CB-839 (200 mg/kg) plus rapamycin
(4 mg/kg) (n = 20), or 3-BrPA (3 mg/kg) plus CB-839 (200 mg/kg)
(n = 18). Vehicle or CB-839 was administered twice daily via gavage,
and 3-BrPA or rapamycin was administered 5 times a week via
intraperitoneal injection. Following treatment, mice were sacrificed for
assessment of tumor burden and analysis of protein expression and
phosphorylation in the kidneys. Vehicle and CB-839 were supplied by
Calithera Biosciences, Inc., South San Francisco, CA. Rapamycin was
purchased from LC Laboratories, Woburn, MA, and 3-BrPA was from
Sigma-Aldrich, Dorset, UK.
Histology
Assessment of tumor burden in the kidneys of mice was performed as
described previously [18]. Mouse kidneys were fixed in 10% buffered
formalin saline (Thermo Scientific, Runcorn, UK) for 24 hours. Fixed
kidneys were processed and paraffin embedded. Six coronal sections of
5 μm were prepared at 200-μm intervals from each kidney. Kidney
sections were hematoxylin and eosin (HE)–stained and scanned to
create virtual slides using an Aperio system (http://www.aperio.com/?
gclid = CNXN-8by4a UCFcINfAods3eg1w). Virtual slides were used
to quantify lesions for tumor burden estimation. Maximum cross-
sectional whole area (lesion size) and cellular area of each renal lesion
were measured using ImageJ (http://rsbweb.nih.gov/ij). Cellular areas
of renal lesions were obtained from parenchyma and stroma. Tumor
burdens for all lesions (cystic/papillary adenomas and solid carcinomas)
and solid carcinomas alone were estimated, respectively. Analysis was
conducted blindly with respect to treatment status.
Immunohistochemistry (IHC)
Kidney sections prepared as described above were used for IHC.
Conventional IHC was performed as described previously [19].
Multiple sequential IHC (MS-IHC) was performed to colocalize
multiple antigens in the same cells using the same tissue sections. Acrucial step of MS-IHC was to completely strip previous primary
antibodies to ensure efficiency and specificity of subsequent primary
antibody-antigen reactions. The protocol used for stripping antibod-
ies was modified from Kim et al. [20]. For MS-IHC, previous IHC-
stained slides were incubated in xylene for 10 minutes to remove
coverslips and then incubated at 50°C in a buffered solution
containing 5% SDS, 0.5% mercaptoethanol, and 50 mm Tris-HCl
(pH 7.5) for 60 minutes to strip antibodies, and finally, the protocol
was followed for conventional IHC. Primary antibodies against
GAPDH, HK2 and glutamate dehydrogenase (GDH), and phos-
phorylated S6 ribosomal protein at S235/236, 4E-BP1 at T37/46,
and Akt at S473 were supplied by Cell Signalling Technology,
Danvers, MA; phosphorylated PKCα at S657 by Santa Cruz
Biotechnology Inc., Dallas, TX; GLS, Ki67, and active Caspase-3
by Abcam, Cambridge, UK; and MCT1 by Insight Biotechnology,
Wembley, UK. SignalStain Boost Rabbit specific IHC Detection
Reagent (Cell Signalling Technology, Danvers, MA) and ImmPACT
NovaRED Peroxidase (HRP) Substrate (Vector Laboratories Ltd.,
Peterborough, UK) were used to stain antigens.
Western Blot
ForWestern analysis, proteins of kidney tissues were prepared from
Tsc2+/− mice treated as described above using AllPrep DNA/RNA/
Protein Mini Kit (QIAGEN Ltd-UK, Crawley, UK). Twenty
micrograms of protein per sample was separated on NuPAGE 4%-
12% Bis-Tris Gels (Fisher Scientific UK Ltd., Loughborough, UK)
and transferred onto Hybond ECL Membranes (GE Healthcare UK
Ltd., Little Chalfont, UK). Blots were analyzed with ECL Select
Western Detection Kit (GE Healthcare UK Ltd.), and signals were
detected using Autochemi Imaging System (UVP, Upland, CA). In
addition to primary antibodies described above, primary antibodies
against β-actin and phosphorylated Akt at T450 were supplied by
Cell Signalling Technology, Danvers, MA; phosphorylated mTOR at
S2448 and S2481 by Sigma-Aldrich, Dorset, UK; and PKCα at T638
by Abcam, Cambridge, UK. Horseradish peroxidase–conjugated
secondary antibody against rabbit was supplied by Cell Signalling
Technology, Danvers, MA.
Statistical Analysis
The Mann-Whitney test was performed to compare tumor burden
and proliferation of tumor cells between treatment groups. P b .05
was considered to be statistically significant. Analyses were performed
using GraphPad Prism 7.03.
Results
Aberrant Activation of mTOR Signaling and Expression of
Enzymes Crucial for Glycolysis and Glutaminolysis in Renal
Tumors of Tsc2+/− Mice
Tsc2+/− mice spontaneously develop renal lesions including cystic/
papillary adenomas and solid carcinomas. As reported previously [19],
both mTORC1 and mTORC2 were aberrantly activated in renal
tumors of Tsc2+/− mice as indicated by increased phosphorylation of
ribosomal protein S6 at S235/236, 4E-BP1 at T37/46, Akt at S473,
and PKCα at S657 (Figure 1). GAPDH and HK2 are important
glycolytic enzymes. GLS and GDH are enzymes crucial for
glutaminolysis. As shown in Figure 2, GAPDH was highly expressed
in papillary adenomas and carcinomas. HK2 was less expressed in
papillary adenomas, but its expression was increased in carcinomas
(Figure 2). The GLS level was variable in papillary adenomas and
Figure 1.mTOR signaling in renal tumors of Tsc2+/−mice. Adjacent kidney sections prepared from 14-month-old Tsc2+/−mice were used
for HE and IHC or MS-IHC. The same sections were subjected to three rounds of IHC to detect phosphorylation of S6 at S235/236, 4E-BP1
at T37/46, and Akt at S473. Phosphorylation of PKCα at S657 was stained on a separate adjacent section. Representative stained sections
were presented to show phosphorylation levels of the corresponding proteins in renal lesions. P, papillary adenoma; Ca, carcinoma. Black
lines are scale bars.
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GDH was also observed in papillary adenomas and carcinomas
(Figure 2).
Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis
for Therapy of Renal Tumors in Tsc2+/− Mice
We tested efficacy of dual inhibition of glycolysis and glutamino-
lysis with 3-BrPA and CB-839 for therapy of renal tumors in Tsc2+/−
mice. 3-BrPA is an efficient inhibitor of GAPDH and HK2, and CB-
839 is a potent inhibitor of GLS. We first examined the expression of
monocarboxylate transporter 1 (MCT1) since it is required for
efficient delivery of 3-BrPA to tumor cells [21]. MCT1 was highly
expressed in all tumor cells of renal cystic/papillary adenomas and
carcinomas in Tsc2+/− mice (Figure 3). We then treated Tsc2+/− mice
for 2 months from the age of 12 months as summarized in Table 1.
Three mice treated with 3-BrPA alone, three with combination of3-BrPA and rapamycin, and four with combination of 3-BrPA andCB-
839 were killed due to significant loss of body weight within the first
month of treatment and excluded from further analysis in this study.
Tumor burden was compared by analyzing total number, size,
and cellular areas of all lesions (cystic/papillary adenomas and solid
carcinomas) and solid carcinomas alone, respectively (Figure 4). When
all lesions are analyzed, combination of 3-BrPA and CB-839
significantly reduced overall lesion size (P = .0209) and cellular
area (P = .0397) (Figure 4; Supplementary Table 1). Combination of
3-BrPA and CB-839 appeared to reduce total number of all lesions, but
the reduction did not reach statistical significance. Rapamycin alone or
rapamycin plus 3-BrPA or rapamycin plus CB-839 significantly
reduced total number (P b .0001, P b .0001, P b .0001), size
(P b .0001, P b .0001, P = .0054), and cellular area (P b .0001,
P b .0001, P b .0001) of all lesions (Figure 4; Supplementary
Table 1). Combination of 3-BrPA and CB-839 also significantly
Figure 2. Expression of enzymes crucial for glycolysis and glutaminolysis in renal tumors of Tsc2+/−mice. Kidney sections prepared from
14-month-old Tsc2+/− mice were used for HE and IHC. Protein levels were examined with IHC. Representative stained sections were
presented to show expression levels of GAPDH, HK2, GLS, and GDH in renal tumors. Black lines are scale bars.
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(P = .0226) of solid carcinomas (Figure 4; Supplementary Table 2).
Similarly, rapamycin alone or rapamycin plus 3-BrPA or rapamycin plus
CB-839 again significantly reduced total number (P b .0001,
P b .0001, P b .0001), size (P b .0001, P b .0001, P b .0001), and
cellular area (P b .0001, P b .0001, P b .0001) of solid carcinomas
((Figure 4; Supplementary Table 2). However, 3-BrPA or CB-839
alone did not significantly reduce total number, size, or cellular area
of all lesions or solid carcinomas. Notably, rapamycin or rapamycin plus
3-BrPA or rapamycin plus CB-839 reduced tumor burden moreFigure 3. Expression of MCT1 in renal tumors of Tsc2+/− mice. Kidne
detect MCT1 with IHC. Representative stained sections were present
Black lines are scale bars.effectively than combination of 3-BrPA and CB-839 in terms of total
number, size, and cellular area of all lesions or solid carcinomas alone
(Figure 4, Supplementary Tables 1 and 2).
Effect of Treatment on mTOR Signaling and Proliferation in
Renal Tumors in Tsc2+/− Mice
We first examined the effect of treatment on mTOR signaling in
the kidney tissues by Western blot. We used phosphorylation of S6
ribosomal protein at S235/236 and mTOR at S2448 as readouts for
mTORC1 activity and phosphorylation of Akt at S473, Akt at T450,y sections prepared from 14-month-old Tsc2+/− mice were used to
ed to show MCT1 expression in renal tumors. C, cystic adenomas.
Table 1. Summary of Animal Treatment










Dosage Number of Animals Killed Due to
Loss of Body Weight Within the
First Month of Treatment †
Vehicle 17 8 9 12 14 10 μl/g 0
3-BrPA 19 9 10 12 14 3 mg/kg 3
CB-839 20 9 11 12 14 200 mg/kg 0
Rapamycin 20 8 12 12 14 4 mg/kg 0
3-BrPA+rapamycin 18 8 10 12 14 3 mg/kg+ 4 mg/kg 3
CB-839+rapamycin 20 8 12 12 14 200 mg/kg+ 4 mg/kg 0
3-BrPA+CB-839 18 8 10 12 14 3 mg/kg+ 200 mg/kg 4
* Tsc2+/− mice were treated twice daily with vehicle or CB-839 via gavage and five times a week with 3-BrPA or rapamycin via intraperitoneal injection.
† These mice were killed due to significant loss of body weight within the first month of treatment.
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shown in Figure 5a, rapamycin alone or rapamycin plus 3-BrPA or
rapamycin plus CB-839 reduced phosphorylation of S6 ribosomal
protein, and rapamycin plus 3-BrPA also reduced phosphorylation ofFigure 4. Efficacy of treatment on renal tumors of Tsc2+/−mice.Tsc2+
vehicle (n = 17), 3-BrPA (n = 19), CB-839 (n = 20), rapamycin (n = 2
3-BrPA+CB-839 (n = 18). Three mice from the 3-BrPA group, three m
BrPA+CB-839 group were euthanized due to significant loss of body w
analysis in this study. Dosages are described in methods. After treatm
treatment efficacy. Left panel: comparison of total number and size (a
Right panel: comparison of total number and size (area) as well as cell
detailed statistical analysis, see Supplementary Tables 1 and 2.mTOR at S2448. Combination of 3-BrPA and CB-839 reduced
phosphorylation of S6 ribosomal protein although to a lesser degree
(Figure 5a). Rapamycin in combination with 3-BrPA or with CB-839
reduced phosphorylation of Akt at S473 and mTOR at S2481, but/−mice were treated from 12 months old for 2 months in 7 groups:
0), 3-BrPA+rapamycin (n = 18), CB-839 + rapamycin (n = 20), and
ice from the 3-BrPA+rapamycin group, and four mice from the 3-
eight within the first month of treatment and excluded from further
ent, kidney sections were prepared for histological assessment of
rea) as well as cellular area of all lesions (cystic, papillary, and solid).
ular area of solid carcinomas. Horizontal bars indicate a median. For
Figure 5. Effect of treatment on mTOR activity in normal tissues and tumors of the kidneys in Tsc2+/− mice. (a) Western blot analysis.
Proteins were prepared from normal kidney tissues of 14-month-old Tsc2+/− mice treated as described above. Beta-actin was used as a
loading control. Representative Western blots were presented to show phosphorylation of mTOR at S2448 and S2481, S6 at S235/236,
4E-BP1 at T37/46, Akt at T450 and S473, and PKCα at T638. (b) MS-IHC analysis. Kidney sections were prepared from 14-month-old Tsc2+/−
mice treated asdescribed above. The samesectionswereused to stain phosphorylationof S6 at S235/236 andAkt at S473. RepresentativeMS-
IHC–stained sections were presented to show phosphorylation of S6 at S235/236 and Akt at S473 in renal tumors. Black lines are scale bars.
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phosphorylation of Akt at T450 or PKCα at T638 were observed in
the kidney tissues after treatment.
We then assessed effect of treatment on mTOR signaling in renal
tumors of Tsc2+/− mice by MS-IHC. Similarly, we used phosphor-
ylation of S6 ribosomal protein at S235/236 as a readout for
mTORC1 activity and phosphorylation of Akt at S473 as a readout
for mTORC2 activity. As shown in Figure 5b, rapamycin alone or
rapamycin plus 3-BrPA or rapamycin plus CB-839 consistently
reduced phosphorylation of S6 ribosomal protein in cystic/papillary
adenomas and solid carcinomas. Combination of 3-BrPA and CB-
839 also slightly reduced phosphorylation of S6 ribosomal protein inFigure 6. Effect of treatment on proliferation of renal tumor cells in
Tsc2+/− mice treated as described above and stained with antibody a
more renal tumors from each treatment group were randomly selecte
ImageJ, and percentage of Ki67-positive cells in total tumor cells was
show expression of Ki67 in tumor cells. Black lines are scale bars. T
positive tumor cells between vehicle and other treatment groups (secystic/papillary adenomas and solid carcinomas (Figure 5b). Rapa-
mycin plus 3-BrPA or rapamycin plus CB-839 substantially reduced
phosphorylation of Akt at S473 in cystic/papillary adenomas and
solid carcinomas (Figure 5b). 3-BrPA alone or 3-BrPA plus CB-839
appeared to reduce phosphorylation of Akt at S473 in cystic/papillary
adenomas and solid carcinomas although to a lesser degree
(Figure 5b). Rapamycin alone reduced phosphorylation of Akt at
S473 in solid carcinomas, but a proportion of rapamycin-treated
cystic/papillary adenomas showed highly phosphorylated Akt at
S473, consistent with previous findings (Figure 5b) [22].
We used Ki67 as a marker to investigate proliferation in renal
tumors of Tsc2+/− mice by IHC (Figure 6). Fifteen or more renalTsc2+/− mice. Kidney sections were prepared from 14-month-old
gainst Ki67 by IHC to assess proliferation of tumor cells. Fifteen or
d for proliferation analysis. Ki67-positive cells were identified using
used for comparison. Representative sections were presented to
he right bottom panel shows comparison of percentage of Ki67-
e Supplementary Tale 3 for detailed statistical analysis.).
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proliferation analysis. Ki67-positive cells were identified using
ImageJ, and percentage of Ki67-positive cells in total tumor cells
was used for comparison. Rapamycin alone, rapamycin plus 3-BrPA,
or rapamycin plus CB-839 substantially reduced the median
percentage of Ki67-positive cells from 16.3% to 2.6%, 1.1%, or
0.9%, respectively (P b .0001) (Figure 6; Supplementary Table 3). 3-
BrPA plus CB-839 also slightly reduced the median percentage of
Ki67-positive cells from 16.3% to 13.3% (P = .0275) (Figure 6;
Supplementary Table 3).
We examined levels of active caspase-3 by IHC to assess apoptosis
in renal tumors of Tsc2+/− mice. We did not observe any consistent
increase in apoptosis in solid carcinomas following treatment
(Supplementary Figure 1). In contrast, reduced levels of active
caspase-3 were observed in tumors treated with rapamycin alone,
rapamycin plus 3-BrPA, or rapamycin plus CB-839. We also noticed
that expression of active caspase-3 was very variable in untreated renal
tumors and larger carcinomas appeared to have more tumor cells
positive for active caspase-3.
Discussion
Upregulated aerobic glycolysis and glutaminolysis are required in
rapidly proliferating tumor cells to meet increased energy demands
and biosynthetic activity [23]. Inhibition of glycolysis or glutamino-
lysis has been investigated for treatment of various types of cancer in
preclinical studies and clinical trials [24,25]. Dual inhibition of
glycolysis with 2-deoxy-glucose and glutaminolysis with aminoox-
yacetate effectively suppressed proliferation of ovarian cancer cells in
vitro [26]. Nonetheless, tumor therapy through dual inhibition of
glycolysis and glutaminolysis has hardly been tested in vivo. In this
study, we tested the efficacy of dual inhibition of glycolysis and
glutaminolysis for therapy of renal lesions in Tsc2+/− mice. 3-BrPA is
an efficient inhibitor of glycolysis by primarily targeting GAPDH and
HK2 [11]. MCT1 is an essential transporter required for 3-BrPA–
mediated inhibition of glycolysis [21]. CB-839 is a potent blocker of
glutaminolysis by selectively inhibiting GLS [13]. We found that
GAPDH, HK2, MCT1, and GLS were all highly expressed in renal
carcinomas. We showed that combination of 3-BrPA and CB-839
significantly reduced overall tumor burden when renal carcinomas or
all renal lesions (cystic/papillary adenomas and carcinomas) were
analyzed in the Tsc2+/− mice. These results suggest that the combined
treatment may be a better strategy for TSC-associated lesions.
However, combination of 3-BrPA and CB-839 was not as efficacious
as rapamycin alone or rapamycin in combination with either 3-BrPA
or CB-839 for these tumors. Furthermore, significant loss of body
weight occurred in some mice treated with 3-BrPA alone,
combination of 3-BrPA and rapamycin, or combination of 3-BrPA
and CB-839, indicating increased toxicity. Combination of CB-839
and everolimus (a rapamycin analog) has previously showed a greater
antitumor activity than everolimus alone in a xenograft mouse model
of renal carcinoma and is currently being tested in patients with renal
carcinoma [16]. However, we did not find a significant difference in
antitumor efficacy between rapamycin alone and rapamycin plus CB-
839 in the Tsc2+/− mice. Rapamycin/rapologs alone are therefore
likely to be the better option for treatment of TSC-associated renal
tumors, while rapalogs combined with CB-839 may improve the
treatment for sporadic RCC.
3-BrPA appeared to reduce the burden of renal carcinomas in
Tsc2+/− mice, but the reduction was not statistically significant. Thisfinding is different from previous observations demonstrating
antitumor efficacy of 3-BrPA for malignancies such as hepatocellular
carcinoma, bladder cancer, nasopharyngeal carcinoma, and renal
carcinoma in vitro and in vivo [12,27–29]. Glycolytic inhibition with
2-deoxyglucose also effectively blocked tumor growth in a mouse
model transplanted with Tsc2-null rat tumor cells [10]. In addition, we
did not observe any reduced burden of renal tumors in theTsc2+/−mice
treated with CB-839. In contrast, CB-839 was very effective for a
variety of cancers in xenograft mouse models [13,15,30], leading to
intensive clinical trials currently under way. The poor response of renal
lesions to 3-BrPA or CB-839 alone in this study may reflect the specific
mechanisms of tumorigenesis in Tsc2+/− mice such as the initiating
mutations of Tsc2 and oncogenic mTOR signaling. The differences
could also be due to xenograft mouse models used in previous studies
that were distinct from genetically altered mice used in this study.
CB-839 has recently been granted Fast Track Designation by the
US Food and Drug Administration for combination with cabozanti-
nib to treat patients with metastatic renal cell carcinoma. Cabozanti-
nib is an inhibitor of multiple tyrosine kinases including vascular
endothelial growth factor receptors (VEGFRs) [31] and has
demonstrated potent antitumor efficacy in a xenograft model of
colorectal cancer through inhibition of angiogenesis and Akt activity
[32]. A recent clinical trial of cabozantinib has shown significantly
improved overall and progression-free survival of patients with
advanced renal cell carcinoma [33]. Expression of VEGFR1 is
increased and Akt is activated in TSC-associated renal tumors
[19,34]. Further investigations may, therefore, be worthwhile to
compare CB-839 combined with cabozantinib with rapamycin or its
analogs for TSC-associated renal lesions in Tsc2+/− mice.
We examined the effect of treatment on mTOR signaling in
normal tissues and tumors from the kidneys of Tsc2+/− mice.
Rapamycin alone or rapamycin in combination with either 3-BrPA or
CB-839 potently inhibited mTORC1, while combination of 3-BrPA
and CB-839 only slightly decreased mTORC1 activity in both
normal and tumor tissues. Such mTORC1 inhibition was associated
with reduced proliferation of tumor cells, possibly accounting for
antitumor activity of these treatments, with rapamycin alone or
rapamycin in combination with either 3-BrPA or CB-839 being
significantly more effective for these tumors in Tsc2+/− mice. Notably,
rapamycin alone or rapamycin in combination with either 3-BrPA or
CB-839 was much more efficient in reducing lesion number than
combination of 3-BrPA and CB-839, consistent with a role of
mTORC1 inhibition in prevention of TSC-associated tumor formation
[19]. CB-839 was reported to substantially decrease mTORC1 activity
in CB-839–sensitive tumor cells of renal carcinomas [16]. However, we
did not observe any inhibitory activity of CB-839 on mTORC1 in
TSC-associated renal tumors, and this could partly explain the lack of
response of these tumors to CB-839 alone. Combination of rapamycin
with 3-BrPA or with CB-839 strongly inhibited mTORC2 in all renal
lesions including cystic/papillary adenomas and solid carcinomas, but
rapamycin alone in contrast increased signaling of mTORC2 in a
proportion of cystic/papillary adenomas. 3-BrPA alone or in combina-
tion with CB-839 also inhibited mTORC2 in all lesions although to a
lesser degree. Feedback increase of mTORC2 activity after rapamycin
treatment is believed to be one of the reasons for limited efficacy [35].
However, inhibition of mTORC2 may promote or suppress death of
tumor cells depending on cellular contexts [36,37]. In addition, no
increased apoptosis was observed in renal tumors treated with any
single or combined compounds in this study. It remains to be further
Neoplasia Vol. 21, No. 2, 2019 Dual Inhibition of Glycolysis and Glutaminolysis Jones et al. 237examined whether inhibition of mTORC2 contributes to antitumor
efficacy in TSC-associated renal lesions.
We conclude that combination of 3-BrPA and CB-839 may not
offer a better therapeutic strategy than rapamycin for TSC-associated
tumors, although the combination therapy significantly reduced
overall size of all renal lesions.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2018.12.003.
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